Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?

BMJ. 2013 Jun 4:346:f3568. doi: 10.1136/bmj.f3568.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Pyrazines / therapeutic use*
  • Triazoles / therapeutic use*

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents
  • Pyrazines
  • Triazoles